Vaxcyte Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2017
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2017
Cost of Revenue	-	75	23	-	-	Upgrade
Gross Profit	-	-75	-23	-	-	Upgrade
Selling, General & Admin	92.9	60.7	39.81	25.26	16.02	Upgrade
Research & Development	476.64	332.34	169.45	78.41	73.56	Upgrade
Operating Expenses	569.55	393.04	209.26	103.67	89.58	Upgrade
Operating Income	-569.55	-468.04	-232.26	-103.67	-89.58	Upgrade
Interest Expense	-	-	-0	-0.01	-0.01	Upgrade
Interest & Investment Income	109.99	62.91	8.36	0.34	0.24	Upgrade
Currency Exchange Gain (Loss)	-	-	-	1.67	-2.35	Upgrade
Other Non Operating Income (Expenses)	-4.38	2.87	0.42	1.59	2.48	Upgrade
EBT Excluding Unusual Items	-463.93	-402.27	-223.49	-100.08	-89.22	Upgrade
Gain (Loss) on Sale of Investments	-	-	-	0	-	Upgrade
Pretax Income	-463.93	-402.27	-223.49	-100.08	-89.22	Upgrade
Net Income	-463.93	-402.27	-223.49	-100.08	-89.22	Upgrade
Net Income to Common	-463.93	-402.27	-223.49	-100.08	-89.22	Upgrade
Shares Outstanding (Basic)	122	97	65	52	30	Upgrade
Shares Outstanding (Diluted)	122	97	65	52	30	Upgrade
Shares Change (YoY)	25.57%	49.75%	24.95%	75.73%	678.53%	Upgrade
EPS (Basic)	-3.80	-4.14	-3.44	-1.93	-3.02	Upgrade
EPS (Diluted)	-3.80	-4.14	-3.44	-1.93	-3.02	Upgrade
Free Cash Flow	-571.79	-364.67	-176.44	-127.95	-47.78	Upgrade
Free Cash Flow Per Share	-4.69	-3.75	-2.72	-2.46	-1.62	Upgrade
EBITDA	-562.54	-464.89	-229.42	-101.87	-88.18	Upgrade
D&A For EBITDA	7	3.16	2.83	1.8	1.41	Upgrade
EBIT	-569.55	-468.04	-232.26	-103.67	-89.58	Upgrade

Updated Feb 25, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q